TTR and neuropathy: Other than surgically, hepatic TTR production can now be targeted by two approved mRNA silencing drugs: patisiran is a small interfering RNA molecule [18] and inotersen an antisense oligonucleotide [19] that both lower serum TTR levels up to 20% of normal, resulting in significant improvement of neuropathy and cardiomyopathy compared to placebo-treated controls.